Jpmorgan Chase & CO Tempest Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Tempest Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 77 shares of TPST stock, worth $672. This represents 0.0% of its overall portfolio holdings.
Number of Shares
77Holding current value
$672% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding TPST
# of Institutions
7Shares Held
846KCall Options Held
400Put Options Held
0-
Black Rock Inc. New York, NY550KShares$4.8 Million0.0% of portfolio
-
Versant Venture Management, LLC San Francisco, CA270KShares$2.36 Million3.26% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ25.7KShares$224,5530.0% of portfolio
-
Cutler Group LP210Shares$1,8330.0% of portfolio
-
Cibc Private Wealth Group, LLC133Shares$1,1610.0% of portfolio
About Tempest Therapeutics, Inc.
- Ticker TPST
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,418,900
- Market Cap $91M
- Description
- Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...